KR20130131095A - Composition for antipruritic and anti-inflammatory effect containing kaemfperol - Google Patents

Abstract

The present invention relates to a composition for antipruritic and anti-inflammatory effects, more specifically the composition which is effective against symptoms of atopic dermatitis by preventing or reducing the pruritus or skin inflammation using kaempferol extracted from bellflower roots as an active component.. [Reference numerals] (AA,DD,GG,JJ) Scratching count (total number / 60 min);(BB,EE,HH,KK) Kaempferol (쨉g/mL);(CC) Compound 48/80(50쨉g/area);(FF) Histamine (100쨉g/area);(II) Serotonin (100μg /area);(LL) Substance P (100μg /area)

Description

Composition for improving skin itch and anti-inflammatory including camphorol {Composition for antipruritic and anti-inflammatory effect containing kaemfperol}

The present invention relates to a composition effective for the prevention and improvement of skin itching or inflammation, and more particularly, by containing camphorol extracted from bellflower as an active ingredient to prevent or alleviate skin itching or inflammation, thereby improving symptoms of atopic dermatitis. It relates to an effective composition.

Mast cells are the major cells that produce inflammatory mediators such as allergic or acute allergic reactions (Kemp, SF and Lockey, RF Anaphylaxis: a review of causes and mechanisms. J. Allergy Clin. Immunol. 110: 341-348, 2002; Galli, SJ, Nakae, S., and Tsai, M. Mast cells in the development of adaptive immune responses.Nat. Immunol. 6: 135-142, 2005). The acute allergic reaction is caused by histamine secretion as the antigen bound to IgE binds to the FcεRI receptor in mast cells. After activation of FcεRI, mast cells begin a degranulation process as a result of secretion of mediators such as arachidonic acid metabolites and inflammatory cytokines (Metcalfe, DD, Kaliner, M). ., and Donlon, MA The mast cell.Crit. Rev. Immunol. 3: 23-27, 1981; Church, MK and Levi-Schaffer, F. The human mast cell.J. Allergy Clin. Immunol. 99: 155- 160, 1997; Kim, SH, Jun, CD, Suk, K., Choi, BJ, Lim, H., Park, S., Lee, SH, Shin, HY, Kim, DK, and Shin, TY Gallic acid inhibits histamine release and proinflammatory cytokine production in mast cells.Toxicol. Sci. 91: 123-131, 2006). Mast cells activated by stimulation of various antigens produce histamine, inflammatory mediators such as eicosanoids, proteoglycans, and proteases, pro-inflammatory cytokines, and chemotactic cytokines. Bradding, P., Feather, IH, Wilson, S., Bardin, PG, Heusser, CH, Holgate, ST, and Howarh, PH Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects.The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation.J. Immunol. 151: 3853-3865, 1993; Galli, SJ, Gordon, JR, and Wershil, BK Cytokine production by mastcells and basophils.Curr. Opin.Imunmun. 3: 865-872, 1991), activation of these mast cells is accompanied by extreme itching.

Compound 48/80 is the most potent substance that stimulates and activates mast cells in connective tissue or skin (Benyon, RC, Robinson, C., Church, MK Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli.Br. J. Pharmacol. 97: 898-904, 1989), histamine secreted from mast cells is known to cause itching (Rukwied, R., Lischetzki, G., McGlone, F., Heyer, G., Schmilz, M. Mast cell mediators other than histamine induce pruritis in atopic dermatitis patterns: a dermal microdialysis study.Br J Pharmacol. 142: 1114-1120, 2000). Serotonin is also known as a substance involved in skin itch-related diseases, and it causes an itch reaction upon subcutaneous injection (Yamaguchi, T., Nagasawa, T., Satoh, M., Kuraishi, Y. Itch-). associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neuroscis res. 35: 77-82, 1999), P is an important itch mediator in studies of atopic dermatitis and causes itching through histamine independent mechanisms (Ohmura, T., Hayashi, T., Satoh, Y., Konomi, A., Jung, B., Sato, H. Involvement of substance P in scratching behavior in an atopic dermatitis model.Eur J Pharmacol. 491: 191-194, 2004).

Itching (pruritus) is a dermatological symptom with severe pain that increases feelings to be scratched and is mainly caused by allergic diseases such as atopic dermatitis (AD) (Beltrani, VS The clinical spectrum of atopic dermatitis.J Allergy Clin Immunol. 104: 87-98, 1999; Raiford, DS Pruritus of chronic cholestasis.QJ Med. 88: 603-607, 1995).

Itching of atopic dermatitis is caused by skin lesions and severe psychological disturbances (Raiford, DS Pruritus of chronic cholestasis. QJ Med. 88: 603-607, 1995). In addition, scratching the affected area due to itching causes the skin barrier to collapse, and repetitive itching worsens the site of inflammation, which is an abnormally activated Th2 of helper / induced T cells. It is caused by an allergic immune response such as not only helper type 2 cells but also mast cells (Wahlgren, CF Itch and atopic dermatitis: an overview. J Dermatol. 26: 770-779, 1999; Kemp, SF. and Lockey, RF Anaphylaxis: a review of causes and mechanisms.J. Allergy Clin Immunol. 110: 341-348, 2002). In particular, mast cells are the major cells that produce inflammatory mediators such as acute allergic reactions (Kemp, SF and Lockey, RF Anaphylaxis: a review of causes and mechanisms. J. Allergy Clin Immunol. 110: 341-348, 2002; Church, MK and Levi-Schaffer, F. The human mast cell.J. Allergy Clin Immunol. 99: 155-160, 1997), this reaction is further activated when the antigen bound to IgE binds to the FcεRI receptor in mast cells. Degranulation occurs and is known to cause severe itching by secreting large amounts of histamine (Church, MK and Levi-Schaffer, F. The human mast cell.J. Allergy Clin Immunol. 99: 155-160, 1997). Therefore, the above-mentioned itch-inducing substance is usefully used for research on diseases accompanied with inflammation and itching such as atopic dermatitis.

The present inventors have tried to find a substance that can prevent and improve inflammation and skin itching, which is a major symptom of atopic dermatitis. As a result, camphorol extracted from bellflower effectively suppresses inflammatory cytokines secreted from mast cells, and also causes skin itching. It was found that there is an excellent inhibitory effect on the action of compound 48/80, histamine, serotonin, P substance and the like, and completed the present invention.

Accordingly, it is an object of the present invention to provide a composition that is safe for skin and can prevent or alleviate skin inflammation and skin itching and is effective in improving the symptoms of atopic dermatitis.

In order to achieve the above object, the present invention provides a composition for the prevention or treatment of atopic dermatitis containing camphorol of the formula (1) as an active ingredient.

[Formula 1]

The composition of the present invention effectively inhibits the inflammatory cytokines secreted from mast cells by containing camphorol extracted from bellflower as an active ingredient, and also in the blood such as compound 48/80, histamine, serotonin, P substance which causes itching Reducing the level has the effect of suppressing skin itching and is therefore effective in improving the symptoms of atopic dermatitis.

1 is a graph showing the effect of camphorol inflammatory cytokine production.
2 is a graph showing the skin itch inhibitory effect of camphorol (M: methiserzid).

The present invention relates to a composition for the prevention or treatment of atopic dermatitis containing camphorol represented by the following formula (1) as an active ingredient. In particular, the composition of the present invention relates to a composition for the prevention or amelioration of inflammation or skin itch.

Camperol used in the present invention is 3,4 ', 5,7-tetrahydroxyflavone (3,4', 5,7-tetrahydroxyflavone), preferably extracted from bellflower.

Platycodon grandiflorum roots have been traditionally used for allergic diseases including asthma in Korea and elsewhere (Choi, JH; Hwang, YP; Lee, HS; Jeong, HG Inhibitory effect of Platycodi Radix on ovalbumin-). induced airway inflammation in a murine model of asthma. Food Chem . Toxicol. 2009, 47 , 1272-1279; Ahn, KS; Noh, EJ; Zhao, HL; Jung, SH; Kang, SS; Kim, YS Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci . 2005, 76 , 2315-2328; Oh YC, Kang OH, Choi JG, Lee YS, Brice OO, Jung HJ, Hong SH, Lee YM, Shin DW, Kim YS, Kwon DY. Anti-allergic activity of a platycodon root ethanol extract. Int J Mol Sci. 2010 Jul 16; 11 (7): 2746-58). In recent years, studies on the extracts of Gil-Gil have been shown to effectively inhibit inflammatory mediators such as nitric oxide (NO) and prostaglandin (Ahn, KS; Noh, EJ; Zhao, HL; Jung, SH; Kang, SS; Kim, YS Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci . 2005, 76 , 2315-2328), as well as inhibiting inflammation-related mediators in the ovalbumin-induced asthma model, have been reported to have anti-allergic effects (Choi, JH; Hwang, YP; Lee, HS; Jeong, HG Inhibitory effect of Radix Platycodi on ovalbumin-induced airway inflammation in a murine model of asthma. Food Chem . Toxicol . 2009, 47 , 1272-1279; Oh YC, Kang OH, Choi JG, Lee YS, Brice OO, Jung HJ, Hong SH, Lee YM, Shin DW, Kim YS, Kwon DY. Anti-allergic activity of a platycodon root ethanol extract. Int J Mol Sci. 2010 Jul 16; 11 (7): 2746-58).

The composition for preventing or treating atopic dermatitis according to the present invention is not particularly limited in its formulation, but may be, for example, a topical skin composition, or a pharmaceutical composition or a health food composition.

In addition, in the case of the pharmaceutical composition according to the present invention, the formulation is not particularly limited, but may be used for parenteral administration such as external application for skin, oral administration, or injection, or as a food additive.

The external preparation composition for skin of the present invention may be formulated as a cosmetic composition and may be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non- It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions may be prepared according to conventional methods in the art.

The pharmaceutical composition according to the present invention may be in the form of a solution, suspension, or emulsion in an oil or an aqueous medium, or in the form of a dry powder which is dissolved in sterile, pyrogen-free water before use, to be used for oral formulation, subcutaneous injection, and intravenous. It may be formulated into a parenteral formulation such as injection or intramuscular injection.

In the case of oral formulations, the compositions of the present invention may be used in known manner using pharmaceutically acceptable carriers and excipients, for example tablets, troches, sugar-containing tablets, aqueous or oily suspensions, dispersible flours or particles. , In the form of emulsions, soft or hard capsules, syrups or elixirs, which can be prepared in unit dosage form and in multi-dose containers to produce the finished product.

In oral formulations, tablets include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and sodium phosphate; Granulating agents such as corn, starch and alginic acid; Disintegration; Binders such as starch, gelatin and acacia; And lubricants such as magnesium stearate, stearic acid and talc, in admixture with excipients usable for the manufacture of tablets. Tablets can be used uncoated or coated to inhibit absorption and degradation of the tablets in the gastrointestinal tract. For example, time-inhibiting substances, such as glyceryl monostearate and glyceryl distearate, can also be applied. Hard capsules are compounds of the present invention mixed with an inert solid diluent such as calcium carbonate, calcium phosphate and kaolin, and soft capsules are solvents such as polypropylene glycol, PEGs (polyethylene glycol) and ethanol, which can be mixed with water. And the active ingredients in oil solvents such as peanut oil, liquid paraffin and olive oil.

The water-soluble suspending agent is a mixture of an active ingredient and an excipient suitable for preparing a water-soluble suspending agent. Examples of the excipient include sodium carboxymethyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinyl- Suspending agents such as ralidon, gum tragacanth and gum acacia; Compounds condensing fatty acids such as polyoxyethylene stearate and alkylene oxides; Compounds in which alkylene oxides are condensed with long fatty acids such as heptadecaethyleneoxycetanol; Compounds which condensate partial esters derived from anhydrous hexitol anhydride and fatty acids, such as polyoxyethylene sorbitol monooleate, with ethylene oxide; Wetting agents; Or dispersing agents. The water-soluble suspending agent may further contain preservatives, colorants, spices and sweeteners.

The oily suspension is a suspension of an active ingredient in a vegetable oil such as olive oil, sesami oil or a mineral oil such as liquid paraffin. For example, a thickening agent such as beeswax, hardened paraffin and cetyl alcohol may be used. It may contain. It may also contain preservatives, colorants, spices, sweeteners, and the like, which can be preserved by adding antioxidants such as vitamin C.

Dispersible powders and particles have an active ingredient in a state of mixing together a dispersing agent, wetting agent, suspending agent and preservative. Suitable dispersing, wetting or suspending agents can be mentioned by way of example already mentioned above. Additional excipients include, for example, sweeteners, spices and colorants.

Water-in-oil emulsions are derived from vegetable oils such as olive oil or mineral oils such as liquid paraffin, and are derived from natural phospholipids such as soy bean lecithin, and esters of anhydrous hecitol or fatty acids such as sorbitan monooleate. And compounds obtained by condensation of ethylene oxide with partial esters derived from anhydrous hexitol anhydride and fatty acids, such as lyoxyethylene sorbitol monooleate, as emulsifiers.

Syrups and elixirs can be prepared by mixing the active ingredients with sweeteners such as glycerol, propylene glycol, sorbitol and sucrose.

Parenteral formulations may be injected as a sterile injectable solution or as a suspension in which the active ingredient is suspended in a non-toxic usable diluent or solvent such as 1,3-butanediol. Among the excipients or solvents that can be used are water, Ringer's solution and isotonic saline solution. Cosolvents such as ethanol, polyethylene glycol, and polypropylene glycol can also be used. In addition, sterile, nonvolatile oils can be customarily used as solvents or suspending solvents. Mixed, non-stimulating, bland fixed oils for this purpose include synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used for the preparation of injectables. Suppository forms are formulated and administered to the rectum by mixing the drug with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, which is solid at room temperature but liquid at the rectal temperature and will melt in the rectum to release the drug. can do.

In addition, when the composition according to the present invention is a health food composition, for example, various foods, beverages, gums, tea, baking, drinks, fats and oils, ice cream, sweets, rice cakes, snacks, baby food, alcoholic beverages, seasonings, retort or It can be formulated into various cooked foods such as canned food, vitamin complexes or health functional foods. Camphorol used in the present invention has almost no toxicity and side effects, so it can be used with confidence even for prolonged administration for prophylactic purposes.

The health food composition of the present invention is not particularly limited to other ingredients except for containing the camphorol as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. As the above-mentioned natural carbohydrate, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol can be used. As sweeteners other than those mentioned above, natural sweeteners (tauumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic sweeteners (saccharin, aspartame, etc.) can be advantageously used. The proportion of carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, carbonation agents used in alcoholic or carbonated beverages, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical but is usually chosen in the range of 0 to 20% by weight, based on the total weight of the composition of the present invention.

The content of camphorol is not particularly limited, but may be used in an amount of 1 to 5,000 mg per dose. In addition, the dosage of the camphorol may be defined within a range of those skilled in the art, the daily dosage of the composition according to the present invention is less than the progression, onset, age, health status, complications, etc. Depending on the various factors of, but generally based on adults 10 to 400 mg / kg, preferably 50 to 200 mg / kg of the composition combined in the above-mentioned weight ratio may be administered once or twice a day The dosage is not intended to limit the scope of the invention in any way.

In addition, when the composition of the present invention is used as a skin external preparation composition, the content of camphorol is not particularly limited, but is 0.001 to 90% by weight, preferably 0.01 to 50% by weight, more preferably based on the total weight of the composition. It may be contained in 0.1 to 10% by weight.

Hereinafter, the present invention will be described more specifically with reference to examples and test examples. These examples are provided only for understanding the contents of the present invention, and the scope of the present invention is not limited to these examples, and modifications, substitutions, and insertions commonly known in the art may be performed. This is also included in the scope of the present invention.

Reference Example 1 Material

1. Reagent

Iscove's modified Dulbecco's medium (fetal bovine serum) was purchased from Gibco BRL (Grand Island, NY, USA). ELISA assay kits such as tumor necrosis factor-α (TNF-α), interleukin (IL) -1, IL-6, IL-8 and histamine were purchased from R & D. Phobol 12-myristate 13-acetate (PMA), calcium ionophore A23187, compound 48/80, P substance, methiserzide maleate, penicillin / streptomycin (P / S) and other reagents are Sigma-Aldrich It was purchased from St. Louis, USA.

2. Separation of plant material and camphorol

The bellflower roots were harvested from Jinan-gun (Jeollabuk-do, South Korea) in June 2011 and identified by Professor Hong-Joon Kim of the School of Oriental Medicine, Woosuk University, and the dried specimens ( ^# 2011-1002) were stored in the specimen management department of Jeonju University. It was.

After immersing well-dried gilpyeong (1,200g) in ethanol (2L) sufficiently and leaving it at room temperature for 14 days, the supernatant was collected and centrifuged at 3,000rpm for 20 minutes, and concentrated using a concentrator (Eyela, Japan). Then, the resultant was dried with a freeze dryer (Eyela, Japan) at -70 ° C to obtain 325 g, and then re-dissolved in organic solvents such as n -hexane, CHCl ₃ , EtOAc, and n -BuOH, fractionated, and each fraction was obtained. Final 190 mg of camphorol was obtained using HPLC (Jaigel 320GS column [Japan Analytical Industry Corp., Tokyo, Japan]). Structural identification of camphorol is described by Singh et al. (Singh, R., Singh, B., Singh, S., Kumar, N., Kumar, S. and Arora, S. Anti-free radical activities of kaempfeol isolated from Acacia nilotica (L.) Willd. Ex. Del. Toxicology in Vitro, 22: 1965-1970, 2008) was used EIMS, ¹ H-NMR, ¹³ C-NMR, the purity was more than 98%.

Camphorol: EI / MS m / z : 286 [M ⁺ ], ¹ H-NMR (400 MHz, CD ₃ OD): δ 8.04 (2H, d, J = 8.8 Hz, H-2 ′, 6 ′), 6.87 (2H, d, J = 8.8 Hz, H-3 ′, 5 ′), 6.35 (1H, d, J = 1.9 Hz, H-8), 6.15 (1H, d, J = 1.9 Hz, H-6 ). ¹³ C-NMR (100 MHz, CD ₃ OD): δ 177.28 (C-4), 165.49 (C-7), 162.45 (C-5), 160.48 (C-4 ′), 158.19 (C-9), 147.97 (C-2), 137.07 (C-3), 130.64 (C-2 ', 6'), 123.70 (C-1 '), 116.25 (C-3', 5 '), 104.51 (C-10) , 99.23 (C-6), 94.45 (C-8).

3. Cell line

HMC-1, derived from human mast cells, was obtained from Jeonju Institute of Biological Materials, 37 ° C, CO ₂ incubator (5% CO ₂ and 95% atmosphere) with sufficient moisture in IMDM containing 10% FBS and 1% P / S. Incubated at.

4. Experimental Animal

Six-week-old female hairless mice were purchased from Orient Bio Co., Ltd. (Seoul, Korea) and used for experiments after adapting to the environment for one week after purchase. Mice were freely fed feed (Central Experimental Animals, Seoul, Korea) and sterilized water by fixing the day and night cycles for 12 hours, and maintaining the temperature and humidity at 22 ± 1 ℃ and 60 ± 5%, respectively. After breeding, it was used for the experiment in accordance with the experimental regulations of the Experimental Animal Committee of Jeonju University.

Test Example 1 Inhibitory Effect of Inflammatory Cytokines

This study examined the effect of camphorol on the production of inflammatory cytokines of HMC-1, a human-derived mast cell line stimulated with PMA and A23187.

Treatment with camphorol at various concentrations (2.5, 5, 10, 20 μg / mL) in HMC-1 (5 × 10 ⁵ / mL) cell suspension, followed by stimulation of 20 nM PMA and 1 μM A23187 simultaneously for 2 hours. , 37 ° C, incubated for 8 hours in a CO ₂ incubator. Thereafter, the cell supernatant was obtained by centrifugation at 1,200 rpm and used for cytokine measurement. Quantification of TNF-α, IL1β, IL-6 and IL-8 was measured according to the method provided by R & D using the ELELIS assay kit for each cytokine. All experimental values were expressed as mean ± standard error, statistical analysis was performed by ANOVA and student's t-test, and the significance limit was set at p <0.05. The measurement results are shown in FIG. 1 (data shown as mean ± SE, ^# p <0.001 for normal control; * p <0.05 for compound 48/80 treatment; ** p <0.01 for treatment with P material alone And *** p <0.01).

As can be seen in FIG. 1, TNF-α (1,010 ± 125 pg / mL), IL-1β (137 ± 8 pg / mL), IL-6 (625 ± 42 pg / mL) of HMC-1 stimulated with PMA and A23187 ) And IL-8 (3,305 ± 291 pg / mL) was significantly increased compared to the normal group with each cytokine base level. However, in the experimental group treated with camphorol, inflammatory cytokines induced by PMA and A23187 were significantly inhibited except in the experimental group administered with a low concentration of 2.5 mg / kg.

Therefore, it can be seen that camphorol has an effect of effectively inhibiting cytokines involved in inflammation such as TNF-α, IL-1β, IL-6, and IL-8.

Test Example 2 Itching Inhibition Effect in Hairless Mice

In this study, we investigated the inhibitory effects of camphorol on the skin itch caused by compound 48/80 or P material, which is an itch-inducing agent, in hairless mice.

Before starting the experiment, five mice per experimental group were placed in a transparent acrylic cage (20 × 26 × 13 cm), respectively, and left in the same experimental environment for 30 minutes for stability. Thereafter, camphorol (2.5, 5, 10, 20 μg / m) or methiserzide maleate (10 mg), known as an itch inhibitor, was orally administered to each mouse and left for 2 hours. At this time, 200 μL oral phosphate buffer solution was orally administered to the normal control group and the positive control group, and left for 2 hours. Subsequently, for the experimental and positive controls, compound 48/80 (50 μg / site), histamine (100 μg / site), serotonin (100 μg / site) or P substance (100 μg / site) was added to the phosphate buffer saline (PBS). Dissolved in the mouse was injected subcutaneously by 0.1 mL each with a 26 gauge syringe at the height between both shoulders of the mouse, to which each extract was administered.

Mice injected with an itch-inducing substance immediately received Mihara (Mihara, K., Kuratani, K., Matsui, T., Nakamura, M. and Yokota, K. Vital role of the itch-scratch response in development of spontaneous dermatitis in NC / Nga mice.Br. J Dermato. 151: 335-345, 2004) using a microcamera (ONCCTV, Seoul, South Korea) for 60 minutes and scratched the site where the itch-causing substance was injected into the hind paws. The count was evaluated by counting by double blind method. Experiments for each trigger were performed on different days and mice used in each experiment were used once. All experimental values were expressed as mean ± standard error, statistical analysis was performed by ANOVA and student's t-test, and the significance limit was set at p <0.05. Results are shown in FIG. 2 (data shown as cumulative mean ± SE of 5 mice, ^# p <0.001 for normal control; * p <0.05 for compound 48/80 alone treatment; * for P material alone treatment * * p <0.01).

As can be seen in Figure 2, compared to the number of scratches of the normal control, the control group administered a compound 48/80, histamine, serotonin or P substance was significantly increased (p <0.001). However, in the experimental group administered with camphorol, the number of concentration-dependent scrapings was significantly reduced compared to the positive control group. In particular, the 10 mg / kg camphorol administration group can be seen to show an inhibitory effect similar to methyserzide (10 mg / kg), which is well known as an itching inhibitor.

Claims (5)

A composition for the prevention or treatment of atopic dermatitis, containing the camphorol of Formula 1 as an active ingredient.
[Chemical Formula 1]

According to claim 1, wherein the camphorol is a composition for the prevention or treatment of atopic dermatitis, characterized in that derived from bellflower. The composition for preventing or treating atopic dermatitis according to claim 1, wherein the camphorol is used in an amount of 1 to 5,000 mg per dose. The composition of claim 1, wherein the composition prevents or alleviates skin itch. The composition of claim 1, wherein the composition prevents or alleviates skin inflammation.

Images